This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Berman, D. M. Articles by Wu, X. Search for Related Content PubMed PubMed Citation Articles by Berman, D. M. Articles by Wu, X.

A Functional Polymorphism in RGS6 Modulates the Risk of Bladder Cancer

¹ Laboratory of Pathology, National Cancer Institute, Bethesda, Maryland; ² Department of Epidemiology, The University of Texas M. D. Anderson Cancer Center, Houston Texas; and ³ Department of Pharmacology, University of Iowa, Iowa City, Iowa

RGS proteins negatively regulate heterotrimeric G protein signaling. Recent reports have shown that RGS proteins modulate neuronal, cardiovascular, and lymphocytic activity, yet their role in carcinogenesis has not been explored. In an epidemiologic study of 477 bladder cancer patients and 446 matched controls, three noncoding single-nucleotide polymorphisms (SNPs) in RGS2 and RGS6 were each associated with a statistically significant reduction in bladder cancer risk. The risk of bladder cancer was reduced by 74% in those individuals with the variant genotype at all three SNPs (odds ratio, 0.26; 95% confidence interval, 0.09–0.71). When the SNPs were analyzed separately, the RGS6-rs2074647 (CT) polymorphism conferred the greatest overall reduction in risk of bladder cancer (odds ratio, 0.66; 95% confidence interval, 0.46–0.95). These reductions in risk were more pronounced in ever smokers, suggesting a gene-environment interaction. In transfection assays, the RGS6-rs2074647 (CT) polymorphism increased the activity of a luciferase-RGS fusion protein by 2.9-fold, suggesting that this SNP is functionally significant. Finally, we demonstrate that RGS2 transcripts and several splice variants of RGS6 are expressed in bladder cancer cells. These data provide the first evidence that RGS proteins may be important modulators of cancer risk and validate RGS6 as a target for further study.

This article has been cited by other articles:

				M. You, D. Wang, P. Liu, H. Vikis, M. James, Y. Lu, Y. Wang, M. Wang, Q. Chen, D. Jia, et al. Fine Mapping of Chromosome 6q23-25 Region in Familial Lung Cancer Families Reveals RGS17 as a Likely Candidate Gene Clin. Cancer Res., April 15, 2009; 15(8): 2666 - 2674. [Abstract] [Full Text] [PDF]

				M. A. James, Y. Lu, Y. Liu, H. G. Vikis, and M. You RGS17, an Overexpressed Gene in Human Lung and Prostate Cancer, Induces Tumor Cell Proliferation Through the Cyclic AMP-PKA-CREB Pathway Cancer Res., March 1, 2009; 69(5): 2108 - 2116. [Abstract] [Full Text] [PDF]

				E. L. Riddle, B. K. Rana, K. K. Murthy, F. Rao, E. Eskin, D. T. O'Connor, and P. A. Insel Polymorphisms and Haplotypes of the Regulator of G Protein Signaling-2 Gene in Normotensives and Hypertensives Hypertension, March 1, 2006; 47(3): 415 - 420. [Abstract] [Full Text] [PDF]